Annovis Bio receives NYSE notice for failing continued listing standards
ANVS•ANVS•ANVS•ANVS•Annovis Bio received an NYSE notice on October 29, 2026, after its market capitalization averaged $48.4 million and it reported a $4.3 million stockholders’ deficit, below requirements of $50 million each. The company plans to submit a compliance plan within 45 days and target compliance within nine months.
Annovis Bio said it received an NYSE noncompliance notice on October 29, 2026, for falling below the exchange’s $50 million market capitalization and stockholders’ equity requirements. Its average market capitalization over 30 trading days was $48.4 million on October 28, and it reported a $4.3 million stockholders’ deficit as of June 30.
The company plans to submit a compliance plan within 45 days of the notice, targeting compliance within nine months of receipt. NYSE may begin delisting proceedings if the plan is late or rejected; failure to regain compliance also risks suspension and delisting. The notice has no immediate listing impact, and the common stock will carry a “.BC” designation until compliance is restored.
